Ling-Ming Tseng

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

Rebecca Dent, Mafalda Oliveira, Steven J. Isakoff et al. · Breast Cancer Research and Treatment · 2021 · 74 citations

Medicine, Oncology, Pharmacology +14

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

Sara A. Hurvitz, S.-B. Kim, Wei‐Pang Chung et al. · ESMO Open · 2024 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular characteristics of recurrent triple-negative breast cancer

Chung‐Hsin Tsai, Jen-Hwey Chiu, Chu‐Wen Yang et al. · Molecular Medicine Reports · 2015 · 21 citations · Full text

Medicine, Molecular Medicine, Oncology +17

The Taiwan Precision Medicine Initiative provides a cohort for large-scale studies

Hsin‐Chou Yang, Pui–Yan Kwok, Ling-Hui Li et al. · Nature · 2025 · 19 citations · Full text

Life Sciences, Genetics, Genomic Data Analysis +11

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer

Kyong Hwa Park, Sibylle Loibl, Joohyuk Sohn et al. · ESMO Open · 2024 · 17 citations · Full text

Medicine, Oncology, Pharmacotherapy +16